Loading patent…
OwnerSimon L. Goodman, Beate Diefenbach +4inventors
InventorsSIMON L. GOODMAN, BEATE DIEFENBACH, DETLEF GUESSOW, RAJ J. MEHTA, EILISH CULLEN, ALEX BROWN
Estimating the term…
The invention relates to a novel purified recombinant αvβ3 adhesion receptor which shows an unimpaired ligand binding activity, and a process for preparing said soluble non-membrane bound receptor in excellent yields by recombinant techniques using a baculovirus-insect cell expression system. The so-synthesized soluble receptor may be used very easily as screening tool for new therapeutic compounds which may inhibit the natural αvβ3 adhesion receptor. Such therapeutic compounds which can be discovered very easily, fast and without health risk by means of the souluble receptors according to the invention may be, for example, RGD peptides or non-peptidic compounds mimicking the natural ligand epitopes. The invention relates, furthermore, to a corresponding process for preparing recombinant full-length αvβ3 adhesion receptor in excellent yields, additionally using detergents to dissolve the membrane bound receptor from the surface of the host cell.
A purified soluble recombinant αvβ3 adhesion receptor which retains a ligand binding activity.
A human αvβ3 adhesion receptor, obtainable by a process as defined in claim 7.
A receptor of claim 12, wherein the truncated αv chain has a molecular weight of 120 kD (±12 kD) and the truncated β3 chain has a molecular weight of approximately 80 kD (±8 kD), each determined by SDS-PAGE under non-reducing conditions.
A process for preparing a large amount of a highly purified soluble recombinant human αvβ3 adhesion receptor which retains a ligand binding activity, comprising
A process for preparing large amounts of a highly purified intact full-length recombinant human αvβ3 adhesion receptor, comprising
Dependencies are inferred from the claim text.